Efficacy of growth factors for the treatment of peri-implant diseases: a systematic review and meta-analysis by Khouly, Ismael et al.








Efficacy of growth factors for the treatment of peri-implant diseases: a
systematic review and meta-analysis
Khouly, Ismael ; Pardiñas-López, Simon ; Ruff, Ryan Richard ; Strauss, Franz-Josef
Abstract: OBJECTIVES The aim of this study was to conduct a systematic review and meta-analysis
on the efficacy of growth factors (GF) on clinical outcomes after treatment (surgical/non-surgical) of
peri-implant diseases (peri-implant mucositis and peri-implantitis). MATERIALS AND METHODS A
protocol was developed to answer the following focused question: Is there any difference for the use of
GF for treatment of peri-implant diseases versus comparative GF treatment or without GF? Electronic
database and manual searches were independently conducted to identify randomized controlled trials
(RCTs). Publications were selected based on eligibility criteria and then assessed for risk-of-bias using
the Cochrane Handbook. The primary outcome was probing depth (PD) and bleeding on probing (BOP)
reduction along with changes in vertical defect depth (VDD). Changes in clinical attachment level, gingival
recession, and plaque index, among others, were studied as secondary outcomes. Based on primary
outcomes, random-effects meta-analysis was conducted. RESULTS A total of five RCTs were included.
GF enhance the reduction of PD (standardized mean difference (SMD) = - 1.28; 95% confidence interval
(CI) - 1.75, - 0.79; p = < 0.0001) and BOP (SMD = - 1.23; 95% CI - 1.70, - 0.76; p = < 0.0001) in the
management of peri-implant mucositis. For the treatment of peri-implantitis, the use of GF yielded to
significantly greater improvement in VDD (SMD = 0.68; 95% CI 0.22, 1.14; p = 0.004); however, there
were no significant differences in terms of PD (SMD = 0.08; 95% CI - 1.08, 1.26; p = 0.887) and BOP
(SMD = 0.211; 95% CI - 0.20, 0.63; p = 0.317). The overall risk of bias of the included studies was
low to unclear. CONCLUSION The results of the present systematic review suggest that the addition of
GF might enhance the outcomes in the treatment of peri-implant mucositis. However, there is a lack of
evidence for supporting additional benefit of GF managing peri-implantitis. CLINICAL RELEVANCE
Within the limitations of the current systematic review and based on the meta-analyses, (1) the addition
of GF for the treatment peri-implant mucositis might be associated with better outcomes in terms of PD
and BOP, and (2) an additional benefit of GF for the treatment peri-implantitis could not be determined
on the basis of the selected evidence.
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Objectives: The aim of this study was to conduct a systematic review and meta-analysis on 
the efficacy of growth factors (GF) on clinical outcomes after treatment (surgical/non-surgical) 
of peri-implant diseases (peri-implant mucositis and peri-implantitis).    
Materials and methods: A protocol was developed to answer the following focused question: 
Is there any difference for the use of GF for treatment of peri-implant diseases versus 
comparative GF treatment or without GF? Electronic database and manual searches were 
independently conducted to identify randomized controlled trials (RCTs). Publications were 
selected based on eligibility criteria and then assessed for risk-of-bias using the Cochrane 
Handbook. The primary outcome was probing depth (PD) and bleeding on probing (BOP) 
reduction along with changes in marginal bone level (VDD).  Changes in clinical attachment 
level, gingival recession, plaque index, among others were studied as secondary outcomes. 
Based on primary outcomes random-effects meta-analysis was conducted. 
Results: A total of five RCTs were included. GF enhance the reduction of PD (standardized 
mean difference (SMD) = -1.28; 95% confidence interval (CI): -1.75,-0.79; p = < 0.0001) and 
BOP (SMD = -1.23; 95% CI: -1.70, -0.76; p = < 0.0001) in the management of peri-implant 
mucositis. For the treatment of peri-implantitis, the use of GF yielded to significantly greater 
decrease in VDD (SMD = 0.68; 95% CI: 0.22, 1.14; p = 0.004), however there were no 
significant differences in terms of PD (SMD = 0.08; 95% CI: -1.08, 1.26; p = 0.887) and BOP 
(SMD = 0.211; 95% CI: -0.20, 0.63; p = 0.317). The overall risk of bias of the included studies 
was low to unclear. 
Conclusion: The results of the present systematic review suggest that the addition of GF 
might enhance the outcomes in the treatment of peri-implant mucositis. However, there is a 
lack of evidence for supporting additional benefit of GF managing peri-implantitis.  
Clinical Relevance: Within the limitations of the current systematic review and based on the 
meta-analyses: (1) the addition of growth factors for the treatment peri-implant mucositis might 
be associated with better outcomes in terms of probing depth and bleeding on probing, and 
(2) an additional benefit of growth factors for the treatment peri-implantitis could not be 
determined on the basis of the selected evidence.  






Long-term success using dental implants is the ultimate goal in implant dentistry, however, 
biological complications may occur, and peri-implant diseases are among the most frequent 
and challenging ones [1-3]. Peri-implant diseases are plaque-associated pathological 
conditions that affect the tissues surrounding dental implants. They are categorized into 2 
types, peri-implant mucositis and peri-implantitis. Peri-implant mucositis is assumed to 
precede peri-implantitis, and it shows clinical signs of bleeding on probing and inflammation; 
whereas peri-implantitis is characterized by inflammation in the peri-implant mucosa and 
subsequent progressive loss of supporting bone, that could finally lead to implant failure [4]. 
The increasing placement of dental implants has led to an inevitable increase in the 
prevalence of peri-implant diseases. In a recent large-scale cross-sectional study, 32% of 
subjects had peri-implant mucositis and 45% had peri-implantitis [1]. This is of particular 
importance as the most reliable and predictable treatment of peri-implant diseases has not yet 
been described. As a consequence, their management is challenging, particularly for peri-
implantitis. 
Both non-surgical and surgical treatments and regenerative procedures have been used to 
control peri-implant diseases, however with inconsistent results [2]. While non-surgical therapy 
has been performed for the treatment of both peri-implant mucositis and peri-implantitis, 
surgical therapy is often used to treat peri-implantitis. Non-surgical therapy is considered less 
effective than surgical approaches in peri-implantitis [5], nevertheless the mechanism by 
which one therapy outperforms the other has not yet been established. Hence, there is a clear 
demand to refine current treatment protocols to arrest and prevent the progression of these 
lesions. The main goal in the treatment of peri-implant diseases is the decontamination of the 
implant surface and resolution of the inflammatory process thereby arresting the progression 
of loss of supporting bone [6]. However, a decrease in bacterial load to a level that allows 
healing to occur is rather difficult using only mechanical methods since the results also depend 
on the access and the biofilm removal [7]. As a result, adjunctive treatments including growth 
factors have been suggested to improve clinical outcomes [8-14] (Fig. 1).  
Growth factors used in regenerative dentistry to enhance clinical outcomes include enamel 
matrix derivative (EMD) and platelet derivative factors such as platelet-rich fibrin (PRF), 
plasma rich in growth factors (PRGF) among others. [15, 16]. They contain and stimulate a 
variety of bioactive molecules such as vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), transforming growth factor beta (TGF- β) and bone 
morphogenic protein (BMP). The delivery of these growth factors is intended to transiently 
stimulate cells locally, promoting proliferation and differentiation and, consequently, 
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regeneration [16-18]. For example, growth factors have been widely used to treat periodontal 
intrabony and suprabony defects, and to promote bone regeneration and bone augmentation 
[19-27]. Moreover, some studies indicate that these growth factors have antibacterial 
properties, [28, 29] which may provide an additional benefit due to the bacterial origin of peri-
implant diseases. Furthermore, the use of growth factors may improve implant-related 
outcomes such as implant stability and alveolar ridge preservation [30]. However, the 
additional effect of using growth factors in the treatment of peri-implant diseases still remains 
unclear.  
Therefore, the aim of this study is to conduct a systematic review and meta-analysis of 
randomized controlled trials on the efficacy of growth factors for the treatment of peri-implant 
diseases.   
MATERIALS AND METHODS 
Standardized Criteria and Type of Study 
This systematic review study was developed and designed according to the established 
criteria by the Cochrane collaboration [31] as well as the Preferred Reporting Items for 
Systematic Review and Meta-Analysis (PRISMA) criteria [32].  
Registry Protocol 
A review protocol was registered by the International prospective register of systematic 
reviews (PROSPERO) data base under the number CRD42018116547 (available at: 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018116547). 
Criteria for Considering Studies for this Review  
The study question included the following PICO-T criteria: Population (P), Intervention (I), 
Comparison (C), Outcome (O), and Time (T) 
The PICO-T criteria were the following: 
• Population: Adult human subject, undergoing treatment for peri-implant diseases. 
• Intervention: Growth factors in combination with surgical/non-surgical treatment. 
• Comparison: comparative growth factor treatment OR no growth factor. 
• Outcomes:  inflammation resolution in terms of reduction of bleeding on probing, 
probing depth, and bone level (primary outcomes), and related parameters (e.g. 
gingival recession, plaque index, complications, etc.) (secondary outcomes). 
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• Time: at least 3 months after treatment. 
The PICO Question:  
Is there any difference for the use of growth factors for surgical or non-surgical treatment of 
peri-implant diseases, in terms of changes on bleeding on probing, pocket depth and bone 
level, evaluated before and after treatment, versus comparative growth factor treatment or no 
growth factors, in human subjects? 
Eligibility Criteria 
Inclusion criteria:   
Requirement for Inclusion in this study meet the following criteria: 
1. Randomized controlled trials (RCT). 
2. Human adult subjects (≥18 years) undergoing treatments for peri-implant diseases 
using growth factors in at least one study group. 
3. Presence of comparative growth factors treatment group or no growth factors control. 
4. Clearly defined clinical and radiological parameters according to which peri-implant 
disease (peri-implant mucositis and peri-implantitis) diagnosis is made. 
5. Specification of probing depth, bleeding on probing and/or marginal bone levels at least 
3 months after treatment. 
Exclusion criteria:   
Requirement for exclusion in this study meet the following criteria: 
1. Prospective cohort studies, non-randomized controlled clinical trials, retrospective 
cohort studies, case-control studies, case reports, systematic reviews, animal trials, 
letter to editors, in vivo and in vitro studies. 
2. Less than 10 subjects per group. 
Type of outcome measures 
Primary Outcomes: 
The primary outcomes were probing depth reduction (in mm), bleeding on probing reduction 




Secondary outcomes included the following:  
  Changes in clinical attachment levels (in mm). 
  Change in gingival recession (in mm)  
  Changes in plaque index. 
  Changes in gingival index. 
  Changes in keratinized tissue. 
  Post-operative infection. 
  Complications (e.g. wound dehiscence). 
  Patient reported outcome measures (e.g. pain, patient satisfaction and/or quality of 
life). 
  Implant failures. 
  Prosthetic failure. 
  Adverse events related to the use of growth factors. 
Search methods for identification of studies  
Electronics searches  
The literature searches strategy was performed in the PubMed, CINAHL, Embase and 
Dentistry & and Oral Sciences Source (DOSS) electronic databases. Electronic databases 
including articles published up to December 15th, 2019.  
Concepts and subject headings were combined for each of the database searches as detailed 
in Appendix I, with the help of a medical and dental librarian (RM). The search was not limited 
by any restrictions on language or date of publication but limited to “clinical trials”. Primary and 
secondary concepts were developed and searched for all databases. 
Searching other resources 
Hand searching 
The electronic search was complemented by manual searches of reference lists of selected 
articles and related review articles. In addition, hand searching of key related journals from 
January 2000 were performed: Clinical Implant Dentistry and Related Research, Clinical Oral 
Implant Research, Journal of Clinical Periodontology, Journal of Dental Research, Journal of 




Online databases providing information about clinical trials in progress were checked 
(clinicaltrials.gov, centerwatch.com/clinicaltrials, clinicalconnection.com). We also searched 
for unpublished studies in OpenGrey open access database. 
Data collection and analysis 
Selection of studies 
Eligibility assessment was achieved through title and abstract search followed by full text 
review. Titles and abstracts for studies, found through the electronic database search as well 
as hand search and unpublished databases, were reviewed independently by two reviewers 
(SPL, IK) for inclusion conforming to the eligibility criteria.  
After initial review, the full texts were read in detail also by two reviewers, to determine if 
articles were in accordance with all inclusion criteria. If the title and abstract did not provide 
sufficient information regarding the inclusion criteria, then the full-text papers were also 
reviewed. The exclusion criteria justification of the excluded studies was documented. Any 
disagreement was resolved by discussion, consensus and moderated by a third party (FJS). 
Data extraction and management 
Data were extracted by one review author (SPL) using a data form that was specifically 
designed for the present meta-analysis and modified for a second review process as required 
for presentation of additional general characteristics and primary and secondary outcomes. 
All data and data forms were reviewed by a second review author (IK). Consensus meetings 
for the selection of each paper, data collection and examination of the data entry were hold 
until completion of this review. The reviewers worked together to consolidate the data analysis 
of this review. Appendix II delineates the study characteristics recorded in the data extraction 
form. Corresponding authors of the included studies were contacted via email for clarification 
of any missing information and/or clarification of methodology and results. 
Assessment of risks of bias in included studies 
The methodological quality of all included randomized clinical trials was assessed according 
to the Cochrane Handbook for Systematic Reviews of Interventions, Chapter 8 [31]. 
Corresponding authors of the included studies were contacted via email for detailed 
information on study methodology, when key domains were assessed as unclear risk of bias 
by the two reviewers. Any disagreement between the reviewers was resolved after discussion, 
consensus, and by third party (IK). 
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Statistical Analysis  
For each included study, extracted data were entered into a spreadsheet and the standardized 
mean differences (SMD) and errors were calculated (Hedge’s g for bias-corrected SMDs). 
Means and standard deviations for studies reporting medians, minimums, and maximums and 
those reporting medians and interquartile ranges were computed using the method of Wan et 
al [33] and Hozo et al [34].  
Estimates for bleeding on probing and probing depth were calculated by pooling study-specific 
estimates using random effects meta-analyses to account for between study heterogeneity. 
Analysis used the inverse variance method and tau2 estimates for the variance of the 
distribution of true effect sizes were estimated using the DerSimonian-Laird estimator. Vertical 
defect depth showed no evidence of heterogeneity and was analyzed using fixed effects meta-
analysis. Subgroup analyses by condition (peri-implantitis or peri-implant mucositis) were 
analyzed using mixed effects models with random effects within subgroups and fixed effects 
between. When included studies reported multiple endpoints, the last endpoint was used. 
Between-study heterogeneity was assessed using the Q statistic and I2, reflecting the total 
proportion of variability in estimates attributed to heterogeneity. Significant Q statistics or an 
I2 value greater than 75% was considered to be evidence of heterogeneity. For each meta-
analysis, forest plots were generated. 
Statistical analyses and graphics were conducted in R v3.5.2. Statistical tests were two-sided, 
and significance was based off a threshold of p<0.05.  
Results  
An electronic search was completed in the following databases: Pubmed, CINAHL, Embase 
and Dentistry and Oral Science Sources (DOSS). The electronic search yielded a total of 
4,193 results and when duplicates were removed the total results were 2,284 articles. The 
hand search yield to one additional relevant article. Two reviewers (SPL, IK) independently 
screened 2,285 abstracts, ultimately excluding 2,269 articles. Sixteen full text articles were 
reviewed. Eleven of the sixteen articles were excluded as they did not meet eligibility criteria 
(appendix table 1)[35-45].  The remaining five studies were included in the present systematic 
review group [14, 46-49] (Appendix Figure 1).  
Description of included studies 
General characteristics of included studies 
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A total of five trials met the aforementioned eligibility criteria and were included in this 
systematic review. The included studies consisted in 201 patients receiving treatment in 220 
implants. The included trials were carried out in academic clinical settings across the world. 
Average age and gender distributions were comparable across the studies. Study 
characteristics including study design, treatment groups, study site and surgical protocol are 
shown in table 1.  
Three trials examined the effect of using GF during surgical therapy of peri-implantitis, while 
two trials examined the effect of GF during non-surgical therapy of peri-implant mucositis. 
Autogenous Growth Factors were used in two trials for the treatment of peri-implantitis, and 
EMD in three trials (one for treatment of peri-implantitis and two for peri-implant mucositis).   
Surgical treatment of peri-implantitis consisted mainly in mechanical debridement with titanium 
instruments, while implant surface decontamination methods were different in these three 
trials. Pre-treatment was reported in four trials. Definitions of peri-implant diseases were 
slightly different across the trials. Isler et al., 2018 [14] and Hamzacebi et al. 2015 [49] used 
the same definition for peri-implantitis, while Isehed et al 2016 [48] slightly different. Faramarzi 
et al. 2015 and Kashefimehr et al. 2017 used the same definition for peri-implant mucositis 
and mild peri-implantitis [46, 47].  
Effects of interventions  
Tables 2 and 3 summarize the primary and secondary outcomes for included studies 
respectively. 
Individual study outcomes 
Results of primary outcomes 
Peri-implant mucositis 
EMD in non-surgical therapy 
Two studies examined the addition of EMD for the non-surgical treatment of peri-implant 
mucositis. One trial reported statistically significant improvements in terms of PD and BOP 
when EMD was added to non-surgical treatment at 3 months as compared to the control group 
[46]. However, the therapy had a limited effect on both groups. Similarly, in another trial the 
addition of EMD significantly improved the results of the non-surgical therapy in terms of PD 




EMD in surgical therapy 
In one study the addition of EMD to open flap debridement failed to show additional benefits 
in terms of PD, BOP and marginal bone level at 12-month follow-up [48]. The same cohort 
was followed up for 3 and 5 years but still without significant differences for the aforementioned 
clinical parameters [50].  
Concentrated growth factor (CGF) and platelet-rich fibrin (PRF) in surgical therapy 
One RCT examined the clinical benefits of GF membranes versus a regular collagen 
membrane in peri-implantitis defects [14]. The use of growth factor membranes in conjunction 
with DBBM rendered significantly inferior results as compared to DBBM plus collagen 
membrane in terms of PD and vertical defect depth (VDD) but no differences in BOP were 
found at 12 months. In another study, the addition of PRF to open flap debridement rendered 
more favorable results compared to open flap debridement alone in terms of PD [49].   
Results of secondary outcomes 
Peri-implant mucositis 
EMD in non-surgical therapy 
One trial exhibited statistically significant improvements in the levels of local plaque index but 
not in the whole-plaque index when EMD added to non-surgical treatment at 3 months [46]. 
Peri-implantitis 
EMD in surgical therapy 
The addition of EMD to open flap debridement did not significantly improve the results in terms 
of plaque levels, presence of pus (infection) and implant failures as compared to the control 
group at 1-, 3- and 5-year follow-ups [48, 50].  
Concentrated growth factor (CGF) and platelet-rich fibrin (PRF) in surgical therapy 
The use of growth factor membranes in conjunction with DBBM rendered significantly inferior 
results as compared to DBBM plus collagen membrane in terms of CAL but no significant 
differences were found in terms of plaque index, gingival index and mucosal recession at 12 
months follow-up [14]. The addition of PRF to open flap debridement rendered more favorable 
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results compared to open flap debridement alone in terms of CAL at 3 and 6 months [49]. 
Furthermore, PRF significantly increased the keratinized mucosa and significantly reduced 
the recessions after treatment at 6 months [49].  
Pooled Data 
Meta-analysis was attempted for primary and all secondary study outcomes. Results from the 
meta-analysis revealed that GF enhance the reduction of PD (SMD = -1.28; 95% CI: -1.75,-
0.8; p < 0.0001) (Fig. 2) and BOP (SMD = -1.23; 95% CI: -1.71, -0.76; p < 0.0001) (Fig. 3) in 
the treatment peri-implant mucositis. For the treatment of peri-implantitis, the meta-analysis 
reported a significantly greater increase in bone levels (SMD = 0.68; 95% CI: 0.22, 1.14; p = 
0.004) (Fig. 4) by the use of GF, however there were no significant differences in terms of PD 
(SMD = 0.08; 95% CI: -1.09, 1.26; p = 0.887) (Fig.5) and BOP (SMD = 0.21; 95% CI: -0.20, 
0.63; p = 0.317) (Fig. 6). There were no significant differences in terms of PD (SMD = -0.46; 
95% CI: -1.41, 0.49; p = 0.34) (Fig.7) and BOP (SMD = -0.49; 95% CI: -1.31, 0.32; p = 0.23) 
(Fig. 8) combining treatment of peri-implant mucositis and peri-implantitis. Analysis of pooled 
data could not be conducted for any secondary outcomes as, to our knowledge, no other trials 
examining comparative study groups and reporting on comparable outcomes have been 
published.  
Risk of bias of included studies  
All included studies were designed as RCTs. The overall risk of bias of the included studies 
was low to unclear (Fig. 9a). The risk of bias assessed for seven key domains was unclear 
from one to three key domains in three trials (Fig. 9b) [46, 47, 49]. Two studies showed low 
risk of bias in all domains [14, 48].  
Discussion 
Summary of key findings 
This systematic review was focused on evaluating the therapeutic value of growth factors in 
conjunction with non-surgical and surgical modalities for the treatment for peri-implant related 
diseases. Regarding peri-implant mucositis, our meta-analysis showed that the addition of 
EMD rendered superior results relative to the control groups in terms of BOP (SMD = -1.23; 
95% CI: -1.71, -0.76; p < 0.0001). Furthermore, EMD reduced the PD to a higher extent in 
peri-implant mucositis (SMD = -1.28; 95% CI: -1.76,-0.8; p < 0.0001). 
The present meta-analysis, however, indicated that growth factors failed to produce an 
additional benefit in terms of PD (SMD = 0.08; 95% CI: -1.09, 1.26; p = 0.887) and BOP (SMD 
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= 0.21; 95% CI: -0.20, 0.63; p = 0.317) in the treatment of peri-implantitis. Interestingly, the 
current analysis also found that the addition of EMD improved the outcomes in terms of VDD 
in subjects affected by peri-implantitis (SMD = 0.68; 95% CI: 0.22, 1.14; p = 0.0040). 
Quality of the evidence  
The overall risk of bias of the included studies was low to unclear. Two studies showed low 
risk of bias in all domains whereas other two studies only the allocation concealment was 
unclear. Only one study did not provide a detailed report of three key domains. Altogether, 
these observations suggest a plausible bias that raises some doubt about the results. 
Therefore, the information presented in this systematic review should be interpreted with 
caution.  
Potential bias in the review process  
The case definition for peri-implant diseases is highly variable for peri-implant mucositis or 
peri-implantitis and, until recently, there was no single uniform definition of peri-implantitis. 
The recent world workshop of periodontal and peri-implant diseases and conditions has 
provided a definition for peri-implant mucositis and peri-implantitis [51]. However, none of the 
included studies used the proposed definition. Concerning peri-implantitis, two [14, 49] out of 
three studies defined it as follows: PD ≥ 5 mm + ≥ 2 mm of peri-implant bone loss combined 
with BOP. Conversely, Isehed et al. [48] defined peri-implantitis as if the patient had at least 
one implant with PD ≥ 5 mm + ≥ 3 mm of peri-implant bone loss. This difference in case 
definition may have an impact on the outcomes and in the extrapolation of the data, especially 
when the definition of peri-implantitis has been questioned [52].  
According to some authors [52], peri-implantitis should be redefined, implying a change of 
paradigm. As such, peri-implantitis would be associated to a foreign body reaction that is not 
counterbalanced by the host-immune response [53]. Consequently, mucositis and bone loss 
around implants may represent normal conditions and not necessarily a state of diseases [52]. 
Hence, the question arises whether the patients included in the present review really suffered 
from a disease and not just an immune response.  
Agreements and disagreements with other previously published articles   
To date, there are few studies evaluating the effect of GF in the treatment of peri-implant 
diseases. Consequently, the comparison with other reviews in terms of disease resolution 
outcomes is limited.  
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In general, the additional effect of GF in terms of BOP and PD reduction are considerably 
better as compared to previous systematic reviews for peri-implant mucositis treatment. 
Outcomes from one systematic review showed that the adjunctive or alternative use of glycine 
powder air polishing failed to provide an additional improvement in BOP in the treatment of 
PIM [54]. Similarly, findings from another systematic review indicated that adjunctive 
antiseptics/antibiotics (local and systemic) does not improve BOP and PD significantly [55], 
and outcomes of a more recent systematic review suggest that non-surgical treatment is 
effective for peri-implant mucositis independent of adjunctive therapy (e.g., local antiseptics, 
systemic antibiotics, air abrasive device) [56]. This differs from the results obtained by the 
current review since reduction of BOP and PD in peri-implant mucositis was not achieved 
without the addition of GF. Indeed, a 3-month RCT indicates that non-surgical debridement 
yields a complete resolution of BOP in only 38% of the implants diagnosed with peri-implant 
mucositis [57]. 
With respect to peri-implantitis, the current data synthesis revealed that the addition of GF 
failed to provide an additional effect in BOP and PD. This lack of difference might be explained 
due to methodological discrepancies between the selected studies. For example, Isler et al. 
[48, 50] used GF in conjunction with bone grafts, while the other studies [48-50] did not include 
bone grafting procedures. This may have influenced the potential benefit of GF. Furthermore, 
one of the included studies was underpowered for the chosen design, thereby impeding the 
detection of an effect [48, 50]. However, the results of the present meta-analysis are in line 
with recent systematic reviews focused on different therapies for the management of peri-
implantitis. For instance, findings from a systematic review revealed that there was insufficient 
evidence for supporting additional benefit of reconstructive therapy to other treatment 
modalities of peri-implantitis management [58]. Results from another systematic review, which 
evaluated adjunctive measures to conventional treatment of peri-implantitis, failed to show any 
significant differences in terms of BOP and PD [55]. These observations were further 
confirmed in a more recent systematic review [59] where the surgical treatment in peri-
implantitis did not provide significant differences in terms of PD or BOP [59].  
Interestingly, the present meta-analysis found that the addition of EMD improved the outcomes 
in terms of VDD in subjects affected by peri-implantitis (SMD = 0.68; 95% CI: 0.22, 1.14; p = 
0.0040). These positive observations match those reported in a case series study where the 
combination of EMD and PDGF in combination with bone grafts increased bone fill [60]. Our 
results are also consistent with a recent systematic review where a surgical procedure with 
implantoplasty improved radiographic outcomes [61]. However, unlike our meta-analysis, the 
authors also reported a significant difference in BOP and PD. Those significant differences 
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could be attributed to the implantoplasty itself and not to the use GF. In fact, the selected 
studies in the present review did not include implantoplasty or any modification of the titanium 
surface. 
Limitations and confounding variables  
The present review has some limitations. First, there was a small number of RCTs using 
growth factors in the treatment of peri-implant diseases. Moreover, most of the studies 
included small sample sizes and were underpowered, thereby reducing the possibility of 
detecting clinically relevant effects. Second, the clinical outcomes following surgical treatment 
of peri-implantitis may depend on the defect morphology. The included studies provided 
limited information on the morphology of treated defects. Third, there were inconsistencies in 
methodology, specifically various treatment modalities with different implant systems along 
with different follow-up periods. Hence, there is a clear demand for randomized controlled 
studies with proper designs and larger sample sizes, comparing the surgical or non-surgical 
treatment of peri-implant diseases with or without growth factors, to provide stronger evidence 
about their possible additional benefit.  
The selected studies included different implants systems, with different surfaces either 
cemented or screw-retained, thereby affecting not only the quality of the decontamination but 
also the flap design. Concerning peri-implantitis, there is some evidence indicating that non-
modified surfaces yield better results following surgical treatment [62, 63] likely due to a 
different bacterial adhesion [64]. For example, the use of antibiotics may have a stronger effect 
in non-modified surface compared to modified ones [63]. To overcome this issue, the removal 
of the modified-surface has been recommended, a procedure termed implantoplasty [65]. 
None of the selected studies included implantoplasty, although multiple surfaces were 
included and in two out of five studies antibiotics were given. This may stand as one of the 
reasons why we failed to find significant difference in terms of BOP and PD in peri-implantitis. 
It should be mentioned, however, that the use of PD as a parameter for disease resolution 
has been questioned [66, 67]. Following treatment of peri-implantitis the resolution of the 
disease may arrest progressive bone loss, reduce BOP and/or suppuration but maintaining 
deep PD due to previous marginal loss [68]. In this sense, a precise physiological PD at 
implant sites is difficult to establish [66]. 
Prosthetic design also plays a pivotal role as the prosthetic design affects the oral hygiene [6], 
however, two out of the six included studies did not provide enough information about the 
restoration which may have influenced the outcomes.  
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The centrifugation force and time lead to different PRF-based matrices with biological 
differences [69]. Consequently, the use of different protocols inevitably complicates the 
comparison between the included studies. In addition, the number of clots or membranes 
utilized during the procedure might influence the clinical outcomes [30, 70]. Isler et al.  [14] 
reported the use of 2 membranes, Hamzacebi et al. [49] did not report it.  
The position of the implants seems to be a predisposing factor to develop peri-implant 
mucositis and peri-implantitis due to the difficulty for oral hygiene [66], nevertheless the type 
of restoration that was performed in each study is unclear. Another controversial aspect is the 
amount of keratinized tissue which may affect the development and the long-term outcomes 
[71-73]. Not every study reported on the amount of keratinized tissue. Recent studies, 
however, have failed to show any significant advantage of the amount of keratinized tissue. 
Conclusions 
Implications for Clinical Practice 
Within the limitations of the current systematic review and based on the meta-analyses: (1) 
the addition of growth factors for the treatment peri-implant mucositis might be associated with 
better outcomes in terms of probing depth and bleeding on probing, and (2) an additional 
benefit of growth factors for the treatment peri-implantitis could not be determined on the basis 
of the selected evidence. Hence, no definite conclusion may be drawn on the use of growth 
factors for the treatment of peri-implant diseases.  
Future research 
There is a need for further properly designed and conducted randomized clinical trials aimed 
at evaluating the effect of different growth factors for the treatment of peri-implant diseases. 
These clinical trials should incorporate the same definition of peri-implant diseases with 
reproductible outcome assessment methods. Additionally, these studies should be conducted 
to assess: 1) the efficacy of growth factors compared to another growth factor or no growth 
factors (or placebo), 2) the efficacy of combining various growth factors during the treatment 
of peri-implant diseases, and 3) the effect of local and systemic factors on outcomes of interest 
such as implant surface, anatomical morphology, soft tissue characteristics, etc.   
 
Clinical Relevance 
Scientific rationale for study: It is not clear if the use of growth factors for surgical or non-
surgical treatment of peri-implant diseases are more effective than comparative growth factors 
treatment or without growth factors.  
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Principal findings: addition of growth factors might enhance the outcomes in the treatment of 
peri-implant mucositis, although its benefit-cost ratio must be further investigated. Practical 
implications:  based on current evidence, no definite conclusion may be drawn on the use of 
growth factors for the treatment of peri-implant diseases. Hence, there is a need for further 
clinical trials aimed at evaluating the effect of different growth factors for the treatment of peri-
implant diseases.  
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Figure 1. Drawing illustrating, step by step, the development and treatment of peri-implantitis: 
A: Healthy implant with intact peri-implant tissues; B: Peri-implantitis showing tissue 
inflammation, bone loss around the implant, bacterial accumulation in the implant surface and 
the macrophagues and lymphocytes activity; C: Bacteria accumulation on the implant surface; 
D: Close-up view of the processes that occur due to peri-implantitis. This includes presence 
of bacteria, soft tissue inflammation, bleeding, osteclastic activity that leads to bone loss; E: 
Mechanical decontamination of the implant surface; F: Treatment of peri-implantitis; G: 
Healing of the peri-implant tissues after treatment; H: Close-up view of the processes that 
occur during healing of the peri-implant tissues. 
Figure 2. Forest Plot for PD outcome in peri-implant mucositis. 
Figure 3. Forest Plot for BOP outcome in peri-implant mucositis. 
Figure 4. Forest Plot for VDD outcome in peri-implantitis. 
Figure 5. Forest Plot for PD outcome in peri-implantitis. 
Figure 6. Forest Plot for BOP outcome in peri-implantitis. 
Figure 7. Forest Plot for PD outcome in both peri-implant mucositis and peri-implantitis. 
Figure 8. Forest Plot for BOP outcome in both peri-implant mucositis and peri-implantitis. 
Figure 9. Review of authors’ judgements about each risk of bias item presented as a a) 
percentage in a graph and b) summary for each included study.   
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